Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance

Trial Profile

LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Letrozole (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms LEEomic
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2019 Planned End Date changed from 28 Dec 2018 to 3 Apr 2019.
    • 31 Jan 2019 Planned primary completion date changed from 28 Dec 2018 to 2 Apr 2019.
    • 31 Jan 2019 Planned initiation date changed from 30 Oct 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top